Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027PRINCETON, N.J., Nov. 17, 2026 // -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines targeting the melanocortin receptor ("MCR") system, today an…